Phase II clinical study of the SGC001 innovative drug “Expected Severe Acute Pancreatitis”, a subsidiary of Hejing Biotech (688068.SH), completed the first patient enrollment and administration

Zhitong Finance App News, Hotjing Biotech (688068.SH) announced that recently, the first clinical study on the indications of the innovative drug SGC001 injection “expected severe acute pancreatitis” independently developed by Beijing Shunjing Biomedical Technology Co., Ltd. (“Shunjing Pharmaceutical”), a holding subsidiary of the company, completed the first case of enrolling the subjects.

The SGC001 target antibody developed by Shunjing Pharmaceutical in collaboration with the Beijing Institute of Cardiopulmonary Vascular Diseases of Anzhen Hospital added the first “expected severe acute pancreatitis” indication phase II clinical study, marking that this major drug candidate with potential first-in-class (FIC) value has entered the multi-indication clinical development stage. This is another important advance made by SGC001 after advancing clinical research in the field of acute myocardial infarction.